Search
Remacemide
go.drugbank.com/drugs/DB06458ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsMitumomab
go.drugbank.com/drugs/DB06462ExperimentalMitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.
IR502
go.drugbank.com/drugs/DB06463ExperimentalIR502 (Zorcell) is a potential treatment for psoriasis.
Sibrotuzumab
go.drugbank.com/drugs/DB06474InvestigationalSibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Propentofylline
go.drugbank.com/drugs/DB06479ExperimentalCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingRopidoxuridine
go.drugbank.com/drugs/DB06485InvestigationalRopidoxuridine is a novel, orally available, thymidine analogue and prodrug for IUdR, which demonstrated a survival advantage in Phase II studies in anaplastic astrocytoma, a type of brain tumor.
Synonyms: 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODOPYRIMIDIN-2(1H)-ONE, 2(1H)-PYRIMIDINONE, 1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-5-IODO-Categories: Heterocyclic Compounds, 1-RingIGN101
go.drugbank.com/drugs/DB06500ExperimentalIGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.
Muraglitazar
go.drugbank.com/drugs/DB06510Investigationalin LDL-C levels. … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring